Answers are grounded in this paper and cite their sources.
Background Germline single nucleotide polymorphisms (SNPs) are biomarkers that can be readily measured using DNA from peripheral blood or normal tissue. While SNPs have been associated with survival and cytotoxic chemotherapy response in several cancers, limited data exist on the clinical relevance of selected SNPs in oesophageal cancer (OeC) patients. Methods DNA was extracted from normal tissue of 480 OeC patients treated with either surgery alone (S, n = 233) or chemotherapy followed by surgery (CS, n = 247) in the OE02 trial. SNPs in DPYD, OPRT, ERCC1, ERCC2 and XRCC1, GSTP1 and TS were analysed using MassARRAY, Sanger sequencing or gel electrophoresis. Associations with clinicopathological variables and overall survival (OS) were investigated. Results Selected SNP variants were associated with age, tumour differentiation, tumour regression and OS. The OPRT rs1801019 ‘GC’ genotype was more frequent in patients aged >65 years (p = 0.034); the TS 5′UTR ‘3R/3R’ genotype was more frequent in poorly differentiated tumours (p = 0.019) and the ERCC2 rs13181 ‘GG’ genotype was nominally associated with improved tumour regression (p = 0.041). In an exploratory analysis, the ERCC1 rs11615 'CT' genotype was associated with improved OS (HR 0.80, 95%CI: 0.65–0.99, p = 0.040) in the whole cohort and in the subgroup of patients with adenocarcinoma treated by surgery alone. No associations were observed for any of the other SNPs. Conclusion In the largest germline SNP analysis in OeC to date, ERCC1 rs11615 ‘CT’ emerged as a candidate prognostic biomarker warranting validation in an independent cohort.
No takes yet. Share an insight, caveat, or question.
Chia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: